Back to Journals » OncoTargets and Therapy » Volume 9

Combination of cold atmospheric plasma and iron nanoparticles in breast cancer: gene expression and apoptosis study

Authors Jalili A, Irani S, Mirfakhraie R

Received 2 September 2015

Accepted for publication 7 January 2016

Published 28 September 2016 Volume 2016:9 Pages 5911—5917


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Haijun Zhang

Peer reviewer comments 4

Editor who approved publication: Dr Faris Farassati

Azam Jalili,1 Shiva Irani,1 Reza Mirfakhraie2

1Department of Biology, Science and Research Branch, Islamic Azad University, 2Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Background: Current cancer treatments have unexpected side effects of which the death of normal cells is one. In some cancers, iron nanoparticles (NPs) can be subjected to diagnosis and passive targeting treatment. Cold atmospheric plasma (CAP) has a proven induction of selective cell death ability. In this study, we have attempted to analyze the synergy between CAP and iron NPs in human breast adenocarcinoma cells (MCF-7).
Materials and methods: In vitro cytotoxicity of CAP treatment and NPs in cells measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cell death was shown by 4',6-diamidino-2-phenylindole and annexin V staining. Fluctuations in BAX and BCL-2 gene expression were investigated by means of real-time polymerase chain reaction.
Results: MTT assay results showed that combination of plasma and iron NPs decreased the viability of cancer cells significantly (P<0.05). Real-time analysis showed that the combination therapy induced shifting the BAX/BCL-2 ratio in favor of apoptosis.
Conclusion: Our data indicate that synergy between CAP and iron NPs can be applied in breast cancer treatment selectively.

Keywords: breast cancer, cold atmospheric plasma, iron nanoparticles, BAX, BCL-2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]